- RIUMA Principal
- Listar por autor
Listar por autor "Koster, Jan"
Mostrando ítems 1-3 de 3
-
Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8+ T cells
Matas-Rico, Elisa; Frijlink, Elselien; Morris, Andrew; Moolenaar, Wouter H; Koster, Jan; van der Haar, Irene; Menegakis, Apostolos; van Zon, Maaike; Salgado-Polo, Fernando; De Kivit, Sander; Johnson, Zoe; Haanen, John; Schumacher, Ton; Borst, Jannie; Verbrugge, Inge; van den Berg, Joost; Perrakis, Anastassis[et al.] (2022)To improve the efficacy of immunotherapy, it is essential to better understand how cytotoxic CD8+ T cells infiltrate into tumors. Here, we examine a role for autotaxin (ATX) in this process. ATX (encoded by ENPP2) is a ... -
Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8+ T cells
Matas-Rico, Elisa; Moolenaar, Wouter H; Frijlink, Elselien; van der Haar Àvila, Irene; Menegakis, Apostolos; van Zon, Maaike; Morris, Andrew J; Koster, Jan; Salgado-Polo, Fernando; de Kivit, Sander; Lança, Telma; Mazzocca, Antonio; Johnson, Zoë; Haanen, John; Schumacher, Ton N; Perrakis, Anastassis; Verbrugge, Inge; van den Berg, Joost H; Borst, Jannie[et al.] (CELLPRESS, 2021)Autotaxin (ATX; ENPP2) produces lysophosphatidic acid (LPA) that regulates multiple biological functions via cognate G protein-coupled receptors LPAR1-6. ATX/LPA promotes tumor cell migration and metastasis via LPAR1 and ... -
Glycerophosphodiesterase GDE2 Promotes Neuroblastoma Differentiation through Glypican Release and Is a Marker of Clinical Outcome
Matas-Rico, Elisa; van Veen, Wouter H; Leyton-Puig, Daniela; van den Berg, Jeroen; Koster, Jan; Kedziora, Katarzyna M; Molenaar, Bas; J A Weerts, Marjolein; de Rink, Iris; Medema, René H; Giepmans, Ben N G; Perrakis, Anastassis; Jalink, Kees; Versteeg, Rogier; van Veen[et al.] (Elsevier, 2016-10)Neuroblastoma is a pediatric embryonal malignancy characterized by impaired neuronal differentiation. A better understanding of neuroblastoma differentiation is essential for developing new therapeutic approaches. GDE2 ...